SCHEMBL5887845

SCHEMBL5887845

CC(C)(C)OC(=O)NC(Cc1ccc(Cl)cc1)C(=O)N1CCC(Cn2cncn2)(C2CCCCC2)CC1

nearest known ligand 0.78

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MC4R P32245 18/20 0.78
MC3R P41968 8/20 0.69
MC1R Q01726 8/20 0.69
MC5R P33032 7/20 0.48
CYP3A4 P08684 1/20 0.44
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887849 1.00 MC4R (0.78) MC4RMC3RMC1RMC5RCYP3A4
SCHEMBL3146775 0.89 MC4R (0.70) MC4RMC3RMC1RMC5RCYP3A4
SCHEMBL3151590 0.88 MC4R (0.80) MC4RMC3RMC1RMC5RCYP3A4
SCHEMBL5934645 0.87 MC4R (1.00) MC4RMC3RMC1RMC5RCYP3A4
SCHEMBL3147970 0.87 MC4R (0.68) MC4RMC3RMC1RMC5RCYP3A4
SCHEMBL3143486 0.87 MC4R (0.78) MC4RMC3RMC1RMC5RCYP3A4
SCHEMBL5934929 0.86 MC4R (0.80) MC4RMC3RMC1RMC5RCYP3A4
Bicarbonate SCHEMBL3149384 0.85 MC4R (0.76) MC4RMC3RMC1RMC5RKMT2A
SCHEMBL5934963 0.85 MC4R (0.77) MC4RMC3RMC1RMC5RCYP3A4
SCHEMBL5934677 0.85 MC4R (0.80) MC4RMC3RMC1RMC5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026335-B2 Melanocortin receptor ligands THE PROCTER & GAMBLE CO. (US) 2006-04-11 US disclosed
US-20050239835-A1 Melanocortin receptor ligands EBETINO FRANK H 2005-10-27 US disclosed
EP-1499588-A1 MELANOCORTIN RECEPTOR LIGANDS THE PROCTER & GAMBLE COMPANY (US) 2005-01-26 EP disclosed
EP-1499314-A1 N-ACYL PIPERIDINE DERIVATIVES FOR USE AS MELANOCORTIN RECEPTOR LIGANDS IN THE TREATMENT OF FEEDING DISORDERS The Procter & Gamble Company (US) 2005-01-26 EP disclosed
US-20040010010-A1 Melanocortin receptor ligands PROCTER & GAMBLE COMPANY, THE 2004-01-15 US disclosed
US-20030236230-A1 Melanocortin receptor ligands THE PROCTER & GAMBLE COMPANY 2003-12-25 US disclosed
WO-2003092690-A1 N-ACYL PIPERIDINE DERIVATIVES FOR USE AS MELANOCORTIN RECEPTOR LIGANDS IN THE TREATMENT OF FEEDING DISORDERS THE PROCTER & GAMBLE COMPANY (US) 2003-11-13 WO disclosed
WO-2003093234-A1 MELANOCORTIN RECEPTOR LIGANDS THE PROCTER & GAMBLE COMPANY (US) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239835-A1 Melanocortin receptor ligands MC1R, MC4R, MC3R MC4R 2/4885MC3R 3/4885MC1R 1/4885
US-20040010010-A1 Melanocortin receptor ligands MC1R, MC4R, MC5R MC4R 2/4885MC3R 4/4885MC1R 1/4885
US-20030236230-A1 Melanocortin receptor ligands MC1R, MC4R, MC5R MC4R 2/4885MC3R 4/4885MC1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.